重组人IgG4-S228P同型对照抗体，体内实验级 | 悉得（Syd Labs） PA007128

描述

了解更多悉得（Syd Labs）人IgG4-S228P同型对照抗体文献，请查看：Syd Labs 人IgG4-S228P同型对照抗体引用文献

人IgG4(S228P)同型对照抗体参考文献:

1. Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders
Stephanie Maciuba,et al.MAbs. 2023.PMCID: PMC10498814
“Prolactin (PRL) has recently been demonstrated to elicit female-selective nociceptor sensitization and increase pain-like behaviors in female animals. Here we report the discovery and characterization of first-in-class, humanized PRL neutralizing monoclonal antibodies (PRL mAbs). We obtained two potent and selective PRL mAbs, PL 200,031 and PL 200,039. PL 200,031 was engineered as human IgG1 whereas PL 200,039 was reformatted as human IgG4. Both mAbs have sub-nanomolar affinity for human PRL (hPRL) and produce concentration-dependent and complete inhibition of hPRL signaling at the hPRL receptor (hPRLR). These two PRL mAbs are selective for hPRL as they do not inhibit other hPRLR agonists such as human growth hormone or placental lactogen. They also cross-react with non-human primate PRL but not with rodent PRL. Further, both mAbs show long clearance half-lives after intravenous administration in FcRn-humanized mice. Consistent with their isotypes, these mAbs only differ in binding affinities to Fcγ receptors, as expected by design. Finally, PL 200,019, the murine parental mAb of PL 200,031 and PL 200,039, fully blocked stress-induced and PRL-dependent pain behaviors in female PRL-humanized mice, thereby providing in vivo preclinical proof-of-efficacy for PRL mAbs in mechanisms relevant to pain in females.”
2. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells
Anders W Matson,et al.J Immunother Cancer. 2024.PMCID: PMC11284835
“Background：Natural killer (NK) cells are being extensively studied as a cell therapy for cancer. These cells are activated by recognition of ligands and antigens on tumor cells. Cytokine therapies, such as IL-15, are also broadly used to stimulate endogenous and adoptively transferred NK cells in patients with cancer. These stimuli activate the membrane protease ADAM17, which cleaves various cell-surface receptors on NK cells as a negative feedback loop to limit their cytolytic function. ADAM17 inhibition can enhance IL-15-mediated NK cell proliferation in vitro and in vivo. In this study, we investigated the underlying mechanism of this process.Methods：Peripheral blood mononuclear cells (PBMCs) or enriched NK cells from human peripheral blood, either unlabeled or labeled with a cell proliferation dye, were cultured for up to 7 days in the presence of rhIL-15±an ADAM17 function-blocking antibody. Different fully human versions of the antibody were generated; Medi-1 (IgG1), Medi-4 (IgG4), Medi-PGLALA, Medi-F(ab′)2, and TAB16 (anti-ADAM17 and anti-CD16 bispecific) to modulate CD16A binding. Flow cytometry was used to assess NK cell proliferation and phenotypic markers, immunoblotting to examine CD16A signaling, and IncuCyte-based live cell imaging to measure NK cell antitumor activity.Results：The ADAM17 function-blocking monoclonal antibody (mAb) Medi-1 markedly increased early NK cell activation by IL-15. By using different engineered versions of the antibody, we demonstrate involvement by CD16A, an activating Fcγ receptor and well-described ADAM17 substrate. Hence, Medi-1 when bound to ADAM17 on NK cells is engaged by CD16A and blocks its shedding, inducing and prolonging its signaling. This process did not promote evident NK cell fratricide or dysfunction. Synergistic signaling by Medi-1 and IL-15 enhanced the upregulation of CD137 on CD16A+ NK cells and augmented their proliferation in the presence of PBMC accessory cells or an anti-CD137 agonistic mAb.Conclusions：Our data reveal for the first time that CD16A and CD137 underpin Medi-1 enhancement of IL-15-driven NK cell activation and proliferation, respectively, with the latter requiring PBMC accessory cells. The use of Medi-1 represents a novel strategy to enhance IL-15-driven NK cell proliferation, and it may be of therapeutic importance by increasing the antitumor activity of NK cells in patients with cancer.”
3. DEspRhigh neutrophils are associated with critical illness in COVID-19
Joanne T. deKay,et al.Sci Rep. 2021.PMCID: PMC8599677
“SARS-CoV-2 infection results in a spectrum of outcomes from no symptoms to widely varying degrees of illness to death. A better understanding of the immune response to SARS-CoV-2 infection and subsequent, often excessive, inflammation may inform treatment decisions and reveal opportunities for therapy. We studied immune cell subpopulations and their associations with clinical parameters in a cohort of 26 patients with COVID-19. Following informed consent, we collected blood samples from hospitalized patients with COVID-19 within 72 h of admission. Flow cytometry was used to analyze white blood cell subpopulations. Plasma levels of cytokines and chemokines were measured using ELISA. Neutrophils undergoing neutrophil extracellular traps (NET) formation were evaluated in blood smears. We examined the immunophenotype of patients with COVID-19 in comparison to that of SARS-CoV-2 negative controls. A novel subset of pro-inflammatory neutrophils expressing a high level of dual endothelin-1 and VEGF signal peptide-activated receptor (DEspR) at the cell surface was found to be associated with elevated circulating CCL23, increased NETosis, and critical-severity COVID-19 illness. The potential to target this subpopulation of neutrophils to reduce secondary tissue damage caused by SARS-CoV-2 infection warrants further investigation.”

悉得（Syd Labs）提供以下体内实验级重组人IgG4-S228P同型对照抗体和突变体（In Vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibodies and Mutants）:

重组人IgG4-S228P同型对照抗体，体内实验级（In Vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody）
重组人IgG4-S228P同型对照抗体，内毒素0.05 EU/mg，体内实验级（In Vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody, Endotoxin 0.05 EU/mg）
重组人IgG4-S228P L235E P329G (SPLEPG)同型对照抗体，体内实验级（In Vivo Grade Recombinant Human IgG4-S228P L235E P329G (SPLEPG) Isotype Control Antibody）
重组人IgG4-S228P L235E P329G (SPLEPG)同型对照抗体，内毒素0.05 EU/mg，体内实验级（In Vivo Grade Recombinant Human IgG4-S228P L235E P329G (SPLEPG) Isotype Control Antibody, Endotoxin 0.05 EU/mg）

悉得（Syd Labs）其它体内实验级重组IgG同型对照抗体和突变体（In vivo grade Recombinant IgG Isotype Control Antibodies and Mutants）:

重组人IgG1同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Human IgG1 Isotype Control Antibody and Mutants）
重组人IgG2同型对照抗体，体内实验级（In vivo Grade Recombinant Human IgG2 Isotype Control Antibody）
重组人IgG3同型对照抗体，体内实验级（In vivo Grade Recombinant Human IgG3 Isotype Control Antibody）
重组人IgG4-S228P同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody and Mutants）
重组小鼠IgG1同型对照抗体和突变体,体内实验级（In vivo Grade Recombinant Mouse IgG1 Isotype Control Antibody and Mutants）
重组小鼠IgG2a同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants）
重组小鼠IgG2b同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2b Isotype Control Antibody and Mutants）
重组小鼠IgG2c同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody and Mutants）
重组小鼠IgG3同型对照抗体，体内实验级（In vivo Grade Recombinant Mouse IgG3 Isotype Control Antibody）
重组大鼠IgG1同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG1 Isotype Control Antibody）
重组大鼠IgG2a同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG2a Isotype Control Antibody）
重组大鼠IgG2b同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG2b Isotype Control Antibody）
重组大鼠IgG2c同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG2c Isotype Control Antibody）

悉得（Syd Labs）体内实验级重组IgG Fc蛋白（In vivo Grade Recombinant IgG Fc Proteins）:

重组人IgG1 Fc蛋白（hIgG1），体内实验级（In vivo Grade Recombinant Human IgG1 Fc Protein （hIgG1））
重组人IgG2 Fc蛋白（hIgG2），体内实验级（In vivo Grade Recombinant Human IgG2 Fc Protein （hIgG2））
重组人IgG4 Fc蛋白（hIgG4），体内实验级（In vivo Grade Recombinant Human IgG4 Fc Protein （hIgG4））
重组小鼠IgG1 Fc蛋白（mIgG1），体内实验级（In vivo Grade Recombinant Mouse IgG1 Fc Protein（mIgG1））
重组小鼠IgG2a Fc蛋白（mIgG2a），体内实验级（In vivo Grade Recombinant Mouse IgG2a Fc Protein （mIgG2a））
重组小鼠IgG2b Fc蛋白（mIgG2b），体内实验级（In vivo Grade Recombinant Mouse IgG2b Fc Protein （mIgG2b））
重组大鼠IgG2a Fc蛋白（rtIgG2a），体内实验级（In vivo Grade Recombinant Rat IgG2a Fc Protein （rtIgG2a））
重组大鼠IgG2b Fc蛋白（rtIgG2b），体内实验级（In vivo Grade Recombinant Rat IgG2b Fc Protein （rtIgG2b））
重组羊驼IgG2b Fc蛋白（lIgG2b），体内实验级（In vivo Grade Recombinant Llama IgG2b Fc Protein（lIgG2b））
重组兔IgG Fc蛋白（rIgG），体内实验级（In vivo Grade Recombinant Rabbit IgG Fc Protein（rIgG））

请记住我们的产品信息: 体内实验级重组人IgG4-S228P同型对照抗体: PA007128 Syd Labs In Vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody。